Healthcare / Diagnostics & ResearchNasdaqCM
$1.75
+0.08 (+4.79%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-7.3M · quality 51.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
28/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$8M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-204.9%
↓Gross Margin
30.8%
↓Debt/Equity
0.16
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2025 · 4 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-153.7%
FCF / Net income
0.63x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $6.1M · net income $-14.9M · FCF $-9.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | $6.1M | $6.1M | $9.4M | $2.5M | $4803.00 | — |
| Net Income | $-14.9M | $-14.9M | $-9.0M | $-7.9M | $-8.2M | $-6.3M |
| EBITDA | $-14.3M | $-14.3M | $-8.3M | $-7.6M | $-5.6M | $-2.2M |
| EPS | -8.66 | -8.66 | -22.50 | -27.30 | -54.30 | -70.80 |
| Gross Margin | 30.8% | 30.8% | 36.1% | 31.3% | 90.3% | — |
| Operating Margin | -174.0% | -174.0% | -95.6% | -314.8% | -83511.5% | — |
| Net Margin | -244.1% | -244.1% | -96.6% | -313.4% | -169771.2% | — |
| Balance Sheet | ||||||
| Debt/Equity | 0.16 | 0.16 | 0.58 | 0.33 | 0.02 | — |
| Current Ratio | 1.36 | 1.36 | — | — | — | — |
| Cash Flow | ||||||
| Free Cash Flow | $-9.4M | $-9.4M | $-7.3M | $-6.1M | $-4.3M | — |
| Returns | ||||||
| ROE | -204.9% | -204.9% | -347.4% | -163.5% | -73.8% | 40.1% |
| Valuation | ||||||
| P/B | 0.41 | 0.41 | 4.38 | 2.76 | 0.65 | — |
| Growth & Yield | ||||||
| Revenue Growth | -34.8% | -34.8% | 269.7% | 52627.4% | — | — |
| EPS Growth | 61.5% | 61.5% | 17.6% | 49.7% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-79.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-22.50 → -8.66
Residual
-79.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.